NewLink-Genentech deal could be worth more than $1bn
This article was originally published in Scrip
NewLink Genetics has been in the news recently for its experimental ebola vaccine, but the Ames, Iowa-based company's stock jumped 7.1% to $31.44 per share on 20 October based on a cancer immunotherapy deal with Genentech potentially worth more than $1bn.
You may also be interested in...
There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.
Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.
Genentech's statements about IDO as an immuno-oncology target raise questions about the future of the drug class, but IDO leader Incyte has emerged unscathed for now.